Prevention cardio-vasculaire chez le patient diabetique de type 2.

Cardiovascular Diseases/etiology/prevention & control; Diabetes Mellitus, Type 2/complications/therapy; Diabetic Angiopathies/prevention & control; Humans; Risk Factors

Abstract :

[en] It is estimated that 80% of individuals with type 2 diabetes die of cardiovascular diseases. Several factors account for the accelerated atherosclerosis present in diabetic patients. These include hyperglycaemia, dyslipidaemia, hypertension and prothrombotic state. Hypoglycaemic agents, statin or fibrates that improve dyslipidaemia, anti-hypertensive agents, aspirin and healthy lifestyle can modify these factors and have been shown to reduce morbidity and mortality caused by coronary heart disease in diabetic patients. It was recently demonstrated that a multifactorial intervention on modifiable risk factors of cardiovascular disease in type 2 diabetic patients dramatically reduces the incidence of cardiovascular events. Thus, an intensified intervention aimed at multiple risk factors should be recommended in patients with type 2 diabetes.

Disciplines :

Cardiovascular & respiratory systems
Endocrinology, metabolism & nutrition

Author, co-author :

Paquot, Nicolas ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Language :

French

Title :

Prevention cardio-vasculaire chez le patient diabetique de type 2.

Alternative titles :

[en] Prevention of cardiovascular disease in type 2 diabetes

Publication date :

2003

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

271-4

Peer reviewed :

Peer reviewed

Additional URL :

http://www.rmlg.ulg.ac.be

Available on ORBi :

since 08 May 2009

Statistics

Number of views

3740 (9 by ULiège)

Number of downloads

3011 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Beckman JA, Creager MA, Libby P. - Diabetes and atherosclerosis. Epidemiology, pathophysiology, and management. JAMA, 2002, 287, 2570-2581.
Haffner SM, Lehto S, Ronnemaa T, et al. - Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with or without prior myocardial infarction. N Engl J Med, 1998, 339, 229-234.
Chiquette E, Chilton R. - Cardiovascular disease: much more aggressive in patients with type 2 diabetes. Curr Atheroscler Rep, 2002, 4, 134-142.
Goldberg RB, Florez H. - Cardiovascular disease in diabetes: prevention and intervention. Curr Opin Endocrinol diabetes, 2001, 8, 101-110.
Solomon CG. - Reducing cardiovascular risk in type 2 diabetes. N Engl J Med, 2003, 348, 457-459.
Scheen AJ, Paquot N. - Rôle spécifique du contrôle glycémique dans la prévention de la macroangiopathie du patient diabétique de type 2. Rev Med Liège, 2003, 58, 265-270.
Beckman JA, Creager MA, Libby P. - Diabetes and atherosclerosis. Epidemiology, pathophysiology, and management. JAMA, 2002, 287, 2570-2581.
Pyoräla K, Pedersen TR, Kjekshus J, et al. - Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care, 1997, 20, 614-620.
Goldberg RB, Mellies MJ, Sacks FM, et al. - Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation, 1998, 98, 2513-2519.
Rubins HB, Robins SJ, Collins D, et al. - Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med, 1999, 341, 410-418.
Heart Protection Study Collaborative Group MCR/BHF. - Heart Protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002, 360, 7-23.
Robins SJ, Collins D, Wittes JT, et al. - Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA, 2001, 285, 1585-1591.
White WB, Prisant ML, Write JT. - Management of patients with hypertension and diabetes mellitus. Advances in the evidence for intensive treatment. Am J Med, 2000, 108, 238-245.
Curb JD, Pressel SL, Cutler JA, et al. - Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA, 1996, 276, 1886-1892.
UK Prospective Diabetes Study (UKPDS) Group. - Efficacity of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39). BMJ, 1998, 317, 720-726.
Heart Outcomes Prevention Evaluation Study Investigators. - Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE and MICRO-HOPE substudy. Lancet, 2000, 355, 253-259.
Hansson L, Zanchetti A, Carruthers G et al. - Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial. HOT Study Group. Lancet, 1998, 351, 1755-1762.
Kjeldsen SE, Dahlof B, Devereux RB, et al. - Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA, 2002, 288, 1491-1498.
Sobol A, Watala C. - The role of platelets in diabetes-related vascular complications. Diabetes Res Clin Pract, 2000, 50, 1-16.
Hulley S, Grady D, Bush T, et al. - Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen Replacement Study (HERS). JAMA, 1998, 280, 605-613.
Herrington DM, Reboussin DM, Brosnihan, et al. - Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med, 2000, 343, 522-529.
Colwell JA. - Aspirin therapy in diabetes. Diabetes Care, 1997, 20, 1767-1771.
American Diabetes Association. - Standards of medical care for patients with diabetes mellitus. Diabetes Care, 2003, 26 (suppl 1), S33-S50.
Tuomilehto J, Lindstrom J, Erickson JG, et al. - Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med, 2001, 344, 1343-1350.
Knowler WC, Barrett-Connor E, Fowler SE, et al. - Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 2002, 346, 393-403.
Williamson DF, Thompson TJ, Thun M, et al. - Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care, 1999, 23, 1499-1504.
Gaede P, Vedel P, Parving HH, et al. - Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 2003, 348, 383-393.
Scheen AJ, Estrella F. - L'étude Steno-2: plaidoyer pour une prise en charge globale et intensive du patient diabétique de type 2. Rev Med Liège, 2003, 58, 109-111.